Conmed (CNMD) is reaffirming its full-year 2025 consolidated revenue and adjusted EPS guidance issued on November 5, 2025. Garner’s planned departure is not the result of any disagreement regarding the company’s financial statements or disclosures
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD:
- Conmed announces 1-for-40 reverse share split
- Conmed price target lowered to $52 from $65 at BofA
- Conmed’s Strategic Exit from Gastroenterology: Hold Rating Amid Portfolio Optimization and Financial Adjustments
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Midday Fly By: Netflix to buy Warner Bros., HP Enterprise posts mixed Q4